Jim D. Durbin

577 total citations
16 papers, 445 citations indexed

About

Jim D. Durbin is a scholar working on Molecular Biology, Genetics and Surgery. According to data from OpenAlex, Jim D. Durbin has authored 16 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Genetics and 4 papers in Surgery. Recurrent topics in Jim D. Durbin's work include Bioactive Compounds and Antitumor Agents (4 papers), Estrogen and related hormone effects (4 papers) and Chemical Synthesis and Analysis (3 papers). Jim D. Durbin is often cited by papers focused on Bioactive Compounds and Antitumor Agents (4 papers), Estrogen and related hormone effects (4 papers) and Chemical Synthesis and Analysis (3 papers). Jim D. Durbin collaborates with scholars based in United States, Russia and Spain. Jim D. Durbin's co-authors include Bryan H. Norman, Jeffrey A. Dodge, Venkatesh Krishnan, Timothy I. Richardson, Anneka Tomlinson, R. E. Coupland, Lance A. Pfeifer, Yong Wang, Yong Wang and Gregory L. Durst and has published in prestigious journals such as PLoS ONE, Endocrinology and Neuroscience.

In The Last Decade

Jim D. Durbin

13 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jim D. Durbin United States	11	239	109	96	85	63	16	445
Paul DaSilva‐Jardine United States	12	270 1.1×	64 0.6×	91 0.9×	171 2.0×	92 1.5×	16	659
Christopher M. Moxham United States	9	464 1.9×	104 1.0×	49 0.5×	67 0.8×	67 1.1×	10	677
Denise Wilcox United States	11	239 1.0×	43 0.4×	57 0.6×	74 0.9×	87 1.4×	18	472
Pierre Antony France	14	225 0.9×	38 0.3×	69 0.7×	133 1.6×	28 0.4×	20	537
Viviane Bertrand France	13	136 0.6×	86 0.8×	39 0.4×	75 0.9×	22 0.3×	19	523
Marvin D. Bregman United States	15	358 1.5×	145 1.3×	82 0.9×	54 0.6×	154 2.4×	27	651
Kaoru Terai United States	14	254 1.1×	42 0.4×	77 0.8×	22 0.3×	15 0.2×	25	477
Bumsup Lee United States	14	283 1.2×	192 1.8×	57 0.6×	55 0.6×	184 2.9×	21	603
Kazunobu Aoyama Japan	14	199 0.8×	49 0.4×	42 0.4×	17 0.2×	35 0.6×	19	409
Deepa Rungta United States	11	265 1.1×	24 0.2×	65 0.7×	134 1.6×	34 0.5×	17	392

Countries citing papers authored by Jim D. Durbin

Since Specialization

Citations

This map shows the geographic impact of Jim D. Durbin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim D. Durbin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim D. Durbin more than expected).

Fields of papers citing papers by Jim D. Durbin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim D. Durbin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim D. Durbin. The network helps show where Jim D. Durbin may publish in the future.

Co-authorship network of co-authors of Jim D. Durbin

This figure shows the co-authorship network connecting the top 25 collaborators of Jim D. Durbin. A scholar is included among the top collaborators of Jim D. Durbin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim D. Durbin. Jim D. Durbin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Durbin, Jim D., Eric Cui, Amil R. Agarwal, et al.. (2025). Trends in screening and treatment of osteoporosis after periprosthetic fractures from 2010 to 2020. Osteoporosis International. 36(3). 513–519.

Parel, Philip M., Eric Cui, Jim D. Durbin, et al.. (2025). Age stratification of 2-year revision risk following reverse total shoulder arthroplasty: a retrospective, multicenter analysis. Journal of Shoulder and Elbow Surgery. 35(2). e160–e168.

Parel, Philip M., et al.. (2025). GLP-1 agonists are protective against postoperative complications following total knee arthroplasty. The Knee. 57. 77–83.

Hu, Haitao, et al.. (2023). Probing the Binding Mechanism of Acylated Peptides to Human Serum Albumin. ACS Chemical Biology. 18(5). 1158–1167. 3 indexed citations

Strifler, Beth A., Zhanna Druzina, Jim D. Durbin, et al.. (2020). Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody. mAbs. 12(1). 1831880–1831880. 15 indexed citations

Pandya, Priyanka, Robert O. Sayers, Joey Ting, et al.. (2020). Integration of phage and yeast display platforms: A reliable and cost effective approach for binning of peptides as displayed on-phage. PLoS ONE. 15(6). e0233961–e0233961. 8 indexed citations

Jones, Spencer B., Lance A. Pfeifer, Thomas J. Bleisch, et al.. (2016). Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design. ACS Medicinal Chemistry Letters. 7(9). 857–861. 39 indexed citations

Patel, Chetan N., Julian Davies, Jim D. Durbin, et al.. (2016). N+1 Engineering of an Aspartate Isomerization Hotspot in the Complementarity-Determining Region of a Monoclonal Antibody. Journal of Pharmaceutical Sciences. 105(2). 512–518. 15 indexed citations

Durham, Timothy B., Valentine J. Klimkowski, Christopher J. Rito, et al.. (2014). Identification of Potent and Selective Hydantoin Inhibitors of Aggrecanase-1 and Aggrecanase-2 That Are Efficacious in Both Chemical and Surgical Models of Osteoarthritis. Journal of Medicinal Chemistry. 57(24). 10476–10485. 21 indexed citations

10.

Jadhav, Prabhakar K., Donald P. Matthews, Michael A. Staszak, et al.. (2014). Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm. ACS Medicinal Chemistry Letters. 5(10). 1138–1142. 50 indexed citations

11.

Norman, Bryan H., Timothy I. Richardson, Jeffrey A. Dodge, et al.. (2007). Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 4: Functionalization of the benzopyran A-ring. Bioorganic & Medicinal Chemistry Letters. 17(18). 5082–5085. 36 indexed citations

12.

Richardson, Timothy I., Jeffrey A. Dodge, Yong Wang, et al.. (2007). Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 5: Combined A- and C-ring structure–activity relationship studies. Bioorganic & Medicinal Chemistry Letters. 17(20). 5563–5566. 31 indexed citations

13.

Richardson, Timothy I., Jeffrey A. Dodge, Gregory L. Durst, et al.. (2007). Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 3: Synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification. Bioorganic & Medicinal Chemistry Letters. 17(17). 4824–4828. 42 indexed citations

14.

Richardson, Timothy I., Bryan H. Norman, Charles W. Lugar, et al.. (2007). Benzopyrans as selective estrogen receptor β agonists (SERBAs). Part 2: Structure–activity relationship studies on the benzopyran scaffold. Bioorganic & Medicinal Chemistry Letters. 17(13). 3570–3574. 30 indexed citations

15.

Efanov, Alexander M., David G. Barrett, Martin Brenner, et al.. (2005). A Novel Glucokinase Activator Modulates Pancreatic Islet and Hepatocyte Function. Endocrinology. 146(9). 3696–3701. 106 indexed citations

16.

Tomlinson, Anneka, Jim D. Durbin, & R. E. Coupland. (1987). A quantitative analysis of rat adrenal chromaffin tissue: Morphometric analysis at tissue and cellular level correlated with catecholamine content. Neuroscience. 20(3). 895–904. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact